U.S. health regulators said late Friday that kid-size doses of Pfizer’s COVID-19 vaccine appear highly effective at preventing symptomatic infections in elementary school children and caused no unexpected safety issues, as the country weighs beginning vaccinations in youngsters.
The Food and Drug Administration posted its analysis of Pfizer’s data ahead of a public meeting next week to debate whether the shots are ready for the nation’s roughly 28 million children ages 5 to 11. The agency will ask a panel of outside vaccine experts to vote on that question.
In their analysis, FDA scientists concluded that in almost every scenario the vaccine’s benefit for preventing hospitalizations and death from COVID-19 would outweigh any serious potential side effects in children. But agency reviewers stopped short of calling for Pfizer’s shot to be authorized.
The agency will put that question to its panel of independent advisers next Tuesday and weigh their advice before making its own decision.
U.S. children could begin vaccinations next month
If the FDA authorizes the shots, the Centers for Disease Control and Prevention will make additional recommendations on who should receive them the first week of November. Children could begin vaccinations early next month — with the first youngsters in line fully protected by Christmas.
Full-strength Pfizer shots already are recommended for anyone 12 or older, but pediatricians and many parents are anxiously awaiting protection for younger children to stem infections from the extra-contagious delta variant and help keep kids in school.
WATCH | Pfizer releases clinical trial data for COVID-19 vaccine for children aged 5 to 11:
The FDA review affirmed results from Pfizer posted earlier in the day showing the two-dose shot was nearly 91 per cent effective at preventing symptomatic infection in young children. Researchers calculated the figure based on 16 COVID-19 cases in youngsters given dummy shots versus three cases among vaccinated children. There were no severe illnesses reported among any of the youngsters, but the vaccinated ones had much milder symptoms than their unvaccinated counterparts.
Most of the study data was collected in the U.S. during August and September, when the delta variant had become the dominant COVID-19 strain.
No new side effects
The FDA review found no new or unexpected side effects, which mostly consisted of sore arms, fever or achiness that teens experience.
However, FDA scientists noted that the study wasn’t large enough to detect extremely rare side effects, including myocarditis, a type of heart inflammation that occasionally occurs after the second dose.
The agency used statistical modelling to try to predict how many hospitalizations and deaths from COVID-19 the vaccine would prevent versus the number of potential heart side effects it might cause. In four scenarios of the pandemic, the vaccine clearly prevented more hospitalizations than would be expected from the heart side effect. Only when virus cases were extremely low would the vaccine cause more hospitalizations than it would prevent. But overall, regulators concluded that the vaccine’s protective benefits “would clearly outweigh” its risks.
While children run a lower risk of severe illness or death than older people, COVID-19 has killed more than 630 Americans 18 and under, according to the CDC. Nearly 6.2 million children have been infected with the coronavirus, more than 1.1 million in the last six weeks as the delta variant surged, the American Academy of Pediatrics says.
The Biden administration has purchased enough kid-size doses — in special orange-capped vials to distinguish them from adult vaccine — for the nation’s 5- to 11-year-olds. If the vaccine is cleared, millions of doses will be promptly shipped around the country, along with kid-size needles.
More than 25,000 pediatricians and primary care providers already have signed up to get the shots into little arms.
Job growth in Canada exceeded expectations in November – Canada Immigration News
With employment soaring beyond predictions and unemployment dropping to near pre-pandemic levels, new labour force data suggest that Canada is on its way to a full economic recovery.
This past November, Canadian employers added 154,000 jobs to the economy. Last month’s growth exceeded analysts’ predictions of 38,000, which was closer to October levels. The gains pushed employment a full percentage point higher than pre-pandemic levels. Also, unemployment dropped to 6%, which is within 0.3 percentage points of what it was in February 2020.
Data from Statistics Canada’s Labour Force Survey reflect labour market conditions during the week of November 7 to 13. Proof-of-vaccination policies and other public health measures were largely similar to those in October.
Labour shortages persist despite employment gains
Hiring in November was driven by the private sector both in full-time and part-time positions. Even so, Canada is still experiencing labour shortages across sectors like hospitality, retail, and health care. In September, there were roughly one million job vacancies across the country.
Most government COVID-19 financial assistance measures ended in late October. Some analysts say it may have pushed people to accept job offers. Among these measures was the Canadian Recovery Benefit for individuals, which had been accused of discouraging people from returning to work. The Conference Board of Canada says the lack of wage growth was an even greater disincentive, especially in low-wage service industries.
“November’s job growth suggests the withdrawal of the [Canadian Recovery Benefit] may have pushed some workers back into employment though alone this will not be sufficient to address the significant labour shortages affecting several industries,” writes economist Liam Daly.
RBC economist Nathan Janzen wrote that despite the surge in employment there were still “exceptionally low” levels of workers in the service sectors.
“Employment in accommodation & food services edged up 5k from October but is still more than 200k below pre-shock levels,” Janzen wrote. “Travel and hospitality spending has been rebounding, but with the unemployment rate now substantially lower, it is increasingly clear that there are not enough remaining unemployed workers out there to re-fill all of those jobs any time soon.”
© CIC News All Rights Reserved. Visit CanadaVisa.com to discover your Canadian immigration options.
Bitcoin plunges overnight – CTV News
Bitcoin prices plummeted overnight to a low of about US$43,000.
As of 10:30 am EST Saturday, the cryptocurrency had dropped more than 13 per cent in the previous 24 hours, from US$56,294 to US$48,309 — a loss of almost US$8,000.
That’s a stark contrast from its all-time high of just last month, when Bitcoin reached almost US$69,000 on November 9.
It’s a slight rebound from a plunge of more than 17 per cent earlier in the day.
Ether, the second most popular cyrptocurrency, fell almost 10 per cent.
The drop for bitcoin follows a volatile week for financial markets. Global equities and benchmark U.S. bond yields tumbled on Friday after data showed US job growth slowed in November and the Omicron variant of the coronavirus kept investors on edge.
Data from another platform, Coinglass, showed that nearly US$1 billion worth of cryptocurrencies had been liquidated over the past 24 hours, with the bulk being on digital exchange Bitfinex.
Will psychedelics become mainstream? This Calgary company is betting on it – CBC.ca
Danny Motyka discovered his love for chemistry when he was high on LSD back in the mid-2000s. The single tab of blotter acid — emblazoned with images of tongues from the rock band Kiss — set him on a path to push psychedelics out of the shadows.
Now 31, Motyka is the CEO of Psygen, a Calgary business hoping to manufacture synthetic psychedelics for the pharmaceutical industry. While the application of hallucinogens in medicine is in its infancy and remains highly speculative, Motyka and his company of believers are encouraged by renewed interest in the field.
“There’s a huge market opportunity here,” Motyka said.
A spate of early scientific research — along with big injections of cash from wealthy and celebrity investors — has triggered a renaissance of sorts for psychedelics, which for decades were pushed underground by the war on drugs.
Companies want to be the next psychedelic unicorn
Dozens of companies have emerged in recent years, seeking to get in on the ground floor of a fledgling industry they bet will take them higher. Some, like Germany-based Atai Life Sciences and the U.K.’s Compass Pathways, have become unicorns — not some kind of hallucination, but the type of startups worth more than $1 billion.
“We’re really breaking ground here in that psychedelic chemistry has been illegal, and now we’re able to do it in a legal context,” said Peter van der Heyden, Psygen’s co-founder and chief science officer.
“It’s never been done before.”
Potential for a new industry
Magic mushrooms, LSD and other psychedelics are hallucinogenic drugs that remain illegal to possess for recreational use. But some regulators such as Health Canada have allowed for research into them as possible treatments for mental health conditions, sending companies and investors on a trip to a new industry.
While the sector initially attracted an early rush of investor enthusiasm, some of the euphoria has already begun to fade as shareholders come to grips with the long and uncertain road ahead.
Researchers are still running clinical trials looking into whether substances like psilocybin, the active ingredient in magic mushrooms, can effectively and safely treat depression, or whether MDMA, often found in ecstasy or molly, can help patients with post-traumatic stress disorder.
“We have to go through the entire drug approval pathway and demonstrate safety and demonstrate efficacy,” van der Heyden said. “So it’s too early, really, to say we know that these things work.”
Production expected early 2022
Psygen’s lab, currently under construction, would initially manufacture psychedelics for research and clinical trials, though it still needs Health Canada approval. The company hopes those trials lead to the creation of new therapeutic drugs, allowing its lab to expand to commercial-scale production of medical-grade substances.
They’ve asked Health Canada for a dealer’s license, which gives special permission to handle and produce controlled drugs that are otherwise illegal to possess. The designation comes with a strict set of rules, including security measures to prevent theft, proper record keeping and reporting.
For now, company officials are optimistic the first phase of the project will secure the green light from federal regulators and they can start producing psychedelics by the end of March 2022.
By then, the facility would be capable of producing 12 to 15 kilograms of synthetic psilocybin a year, enough to fill demand from clinical research, Motyka said.
Marijuana paves the way for mushrooms
The Alberta business has applied to handle eight different psychedelic drugs, though its CEO said psilocybin is the substance most in demand from drug development companies, likely because of loosening cannabis laws.
“That’s reflective of this liberalization of plant medicines. It’s easy to go from cannabis as a medicine to mushrooms as a medicine,” Motyka said. “It’s a bit harder to make that next jump to LSD, especially with the amount of stigma that’s associated.”
Researchers are looking at psilocybin’s potential to treat various conditions, from anxiety and obsessive-compulsive disorder, to problematic substance use. Health Canada, which has approved three clinical trials testing the drug in treatment of depression, said psilocybin has so far shown some promise in some cases, but further research is needed.
“Clinical trials are the most appropriate and effective way to advance research with unapproved drugs such as psilocybin,” the regulator said in a statement.
“Clinical trials ensure that the best interests of patients are protected and that a product is administered in accordance with national and international ethical, medical and scientific standards.”
‘Hungry for something new’
Industry observers say the legalization of cannabis for recreational or strictly medical purposes in many parts of the world has helped to ease stigmas and convince investors to pump hundreds of millions of dollars into psychedelics.
Plus, the outbreak of the deadly COVID-19 virus — and the rounds of restrictions that came with it — triggered a fresh wave of mental health concerns. And it’s happening at a time when people are interested in unconventional ways of looking at problems, said Leila Rafi, a Toronto lawyer with clients in the industry.
“There’s a lot of investors out there who are willing to put a little bit of money into this industry and see what happens — and even take a bit of a hit,” said Rafi, a partner in McMillan’s capital markets group.
“And I think investors are just hungry for something new.”
Psychedelic stocks in a lull
Steve Hawkins, the CEO of financial services company Horizons ETFs, runs a fund that allows people to invest in the broader psychedelics market. The exchange traded fund (ETF) tracks a couple dozen publicly traded companies that are heavily involved in, or have significant exposure to, the industry.
So far, it’s individual investors, rather than big pension funds, that have parked money in the fund, Hawkins said.
“This is still a very early stage investment proposition.”
An initial burst of investor excitement has given way to a lull in recent months, with share prices for drug development firms plunging. The Horizons psychedelics ETF has lost half of its value on the stock market since hitting a peak in February.
In an industry where companies are not making money, stock prices are driven by other developments, including news of breakthroughs in research. But there haven’t been enough intoxicating incentives to lure investors back, Hawkins said, noting that while share prices have fallen from their peaks, they are still above where they were in 2020.
Investors hooked on psychedelic ventures also face plenty of risk.
“All investors who are investing in early stage drug development companies need to be prepared to lose a substantial amount of money– Eric Foster, Dentons lawyer
Firms that are attracting troves of investment dollars are often burning through all that cash researching drugs that may not materialize, Hawkins said. “These are very risky companies.”
Some could fail, similar to what happened in the cannabis industry.
“All investors who are investing in early stage drug development companies need to be prepared to lose a substantial amount of money,” said Eric Foster, a partner at Dentons law firm who helps investment banks finance psychedelic ventures.
“The (potential) upside is that they will be able to take a candidate all the way through the regulatory approval process, and effectively get to a drug that’s been approved … Then, all of a sudden, it’s going to be worth significantly more.”
A new frontier
The very idea that psychedelics could emerge from the shadows of a decades-long drug war and pave the way to a new frontier of medicine has inspired other investors with deep pockets.
Liam Payne, the British One Direction singer, along with PayPal co-founder and billionaire Peter Theil are on the growing list of celebrity investors. New York Mets owner Steven Cohen, Shark Tank’s Kevin O’Leary and Tim Ferriss, the podcaster and author of The 4-Hour Workweek, are also on the roster.
Then there’s Sa’ad Shah. Convinced that researchers are only scratching the surface of psychedelics’ potential power to reshape mental healthcare, he co-founded a venture capital player focused on the industry.
Shah has been raising money from friends, various CEOs and ultra-high-networth investors to build a warchest to unleash on dozens of companies. The Noetic Fund, based in Toronto, raised $32 million US in its first round and invested it into 22 ventures, including Calgary’s Psygen. Now, it’s on the hunt for another $200 million.
Nearly halfway there, Shah said he’s not facing the same kind of investor burnout that has sent stock prices tumbling. He said most of the “crown jewels” in the industry remain privately held companies that continue to raise funds.
“It’s a burgeoning industry,” Shah said. “It’s an incredibly exciting industry. It is a bit of the Wild West.”
An opportunity and a business venture
Van der Heyden, Psygen’s co-founder, says he found a gap in this Wild West landscape when he spoke with researchers who couldn’t get their hands on pharmaceutical-grade psychedelics for their studies. He saw an opportunity.
A child of the hippie era of the 1960s and early 1970s, he said the counterculture movement exposed him to drugs like LSD. But it wasn’t until his retirement that psychedelics became a possible business venture.
And it’s made for some unusual conversations.
“I might be sitting at the barber and he asks me, ‘What do you do?’ And so I say, ‘Hey, guess what? We make psychedelic drugs.'”
More Galleries of Color Debut at Art Basel Miami – The New York Times
Dutch former queen Beatrix tests positive for COVID-19
Hoping Omicron won’t wreck Christmas, Bethlehem lights up tree
Silver investment demand jumped 12% in 2019
Europe kicks off vaccination programs | All media content | DW | 27.12.2020 – Deutsche Welle
Iran anticipates renewed protests amid social media shutdown
Sports9 hours ago
FTB: The Maple Leafs are in Minnesota after a scuffle at practice – Pension Plan Puppets
Health22 hours ago
'I was shocked': Mother, child mistakenly given COVID-19 vaccine instead of flu shot – Vancouver Is Awesome
Tech23 hours ago
PlayStation is reportedly working on its own version of Xbox Game Pass – MobileSyrup
News3 hours ago
Omicron: Should you travel and what insurance will you need? – CTV News
Economy15 hours ago
Can the global economy battle through another COVID-19 setback? – Aljazeera.com
Health23 hours ago
FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly
Economy11 hours ago
Nobody seems to know what's going on with the economy – CNN
Sports22 hours ago
Sheldon Keefe on the Mitch Marner-Jake Muzzin incident in practice: "Our team is really close and that kind of stuff will be shaken off really quickly" – Maple Leafs Hotstove – Maple Leafs Hot Stove